Abbott (NYSE: ABT) has announced the company's schedule of major events and news announcements during EuroPCR 2009 in Barcelona, May 19 - 22. These include the presentation of new data from the SPIRIT V post-approval, single-arm study of the company's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System, as well as new details of Abbott's next-generation drug eluting stent in development,
the XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System.
During the meeting at Abbott's booth (# CO8), physicians will learn more about XIENCE PRIME, which utilizes the same drug and polymer as Abbott's market-leading XIENCE V drug eluting stent and is based upon the proven design of the MULTI-LINK(R) family of stents. Building upon the strong body of clinical evidence from the SPIRIT family of clinical trials, Abbott plans to make XIENCE PRIME available in an expanded size matrix, including XIENCE PRIME SV for small vessels and XIENCE PRIME LL for long lesions. The company expects to launch XIENCE PRIME in Europe later this year.
XIENCE PRIME is pending CE Mark, and is not available for sale.
In addition, Eberhard Grube, M.D., of Heart Center Siegburg, Germany, will present the one-year results from Abbott's 2,663-patient SPIRIT V single-arm study. The data will be presented during the EuroPCR 2009 Drug-Eluting Stent Abstract Session on Thursday, May 21, at 3:06 p.m. CET in Room 118-119 at The Forum CCIB Convention Center in Barcelona.
"We are excited to present the one-year data from the SPIRIT V study. This single-arm trial accurately reflects the broad range of disease seen in a typical catheterization lab and will provide valuable information on how XIENCE V performs in complex lesions in a real-world population," said Charles Simonton, M.D., FACC, FSCAI, divisional vice president, Medical Affairs, and chief medical officer, Abbott Vascular. "In addition, we will be demonstrating the use of XIENCE PRIME, the next innovation from our pipeline, through simulated arterial model (SAM) testing at EuroPCR."
More Featured Products and Programs at Abbott's Booth
-
Prostar XL: Physicians can learn about the Prostar XL Percutaneous Vascular Surgical System vessel closure device, which now has CE Mark for use following minimally invasive procedures that allow large access sites up to 24F in the femoral artery in the upper thigh. The Prostar XL currently is the only vessel closure device with this indication in the European Union.
Emboshield Nav6: Abbott will feature its sixth-generation Emboshield(R) NAV6 Embolic Protection System, which is used during carotid stenting procedures to prevent particles of dislodged plaque from flowing to the brain, potentially causing an ischemic stroke. The advanced design of the Emboshield NAV6 offers simpler procedure preparation and excellent deliverability and visibility under X-ray, providing ease of use even in challenging anatomies.
Bioabsorbable Program: Richard Rapoza, Ph.D., divisional vice president, Bioabsorbable Vascular Solutions Program, Abbott Vascular, will present "The Future of Coronary Stenting: Bioabsorbable Stent Technology" on May 20 and 21 from 12:15 - 12:45 p.m. CET. Dr. Rapoza will discuss Abbott's ABSORB clinical trial, which recently began enrolling patients into the second phase of the trial. Abbott is the only company with long-term clinical data (out to two years) evaluating the safety and performance of a fully bioabsorbable coronary device.
Abbott's market-leading XIENCE V drug eluting stent is marketed in the United States, Europe and other international markets. XIENCE V is an investigational device in Japan and is currently under review by Japan's Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency. Additional information about XIENCE V, including important safety and effectiveness information, is available online at www.xiencev.com. Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its anti-proliferative properties. About Abbott Vascular
Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products. About Abbott
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's Web site at www.abbott.com.